$PI

PI Industries plunges 10%, hits 52-week low on disappointing Q1 results

PI Industries shares fell about 10% to a 52-week low of ₹2,458 in Wednesday trading after its Q1FY27 results. Revenue declined 10% YoY to ₹1,702 crore, EBITDA fell 29% to ₹367 crore, and PAT dropped 39% to ₹244 crore. Brokerages cited weakness in Agchem exports and PI Health Sciences order phasing.

Original reporting
Published Aug 12, 2026, 11:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 11:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PI Industries plunges 10%, hits 52-week low on disappointing Q1 results — source image
Decision brief

The 30-second read

$PIBearishMed
01

Why it matters

The combination of revenue decline, sharp EBITDA drop, and gross margin pressure from higher input costs provides a direct fundamental explanation for the 10% plunge and 52-week low print.

02

Market read

Traders get a same-day earnings datapoint set (revenue, EBITDA, PAT, margins) plus segment-level demand and order-timing drivers that explain the selloff and inform near-term positioning.

03

What to watch

The article notes four marquee CDMO customers added and a large cash balance; traders may re-rate the stock if subsequent commentary confirms order phasing is temporary and margins stabilize.

Relevance 8/10Novelty 7/10Timing: intraday selloff after Q1FY27 results, reported during Wednesday trading

Background

PI Industries reported Q1FY27 (June quarter) results alongside commentary on export softness, domestic volume resilience, and PI Health Sciences order phasing.

Company-level read

Ticker impact

$PIBearishHigh confidence
Context

PI Industries shares fell 10% to a 52-week low after reporting Q1FY27 results with revenue down 10% YoY and EBITDA down 29% YoY.

Expected impact

Near-term bias remains bearish; any relief likely depends on follow-up commentary on export softness, CDMO order phasing, and margin trajectory.

Evidence & confidence

The article provides concrete earnings datapoints (revenue, EBITDA, PAT, margins) plus segment drivers (Agchem exports softness, PI Health Sciences order phasing) that directly explain the sharp intraday selloff.

Market effects

Weakness in agrochemical exports and CDMO order phasing can pressure sentiment across India agrochem and specialty pharma services names with similar demand sensitivity.

May weigh on broader India small/mid-cap industrials/agrochem sentiment if investors generalize margin compression and export softness.

Global agrochemical demand softness and delayed monsoon-led buying are cited, which can reinforce caution on export-exposed chemical producers.

Counterpoint

Management’s medium-to-long-term optimism and claims of stabilizing order book and inventory normalization could limit the downside if the quarter reflects timing rather than structural deterioration.

Key entities

  • PI Industries

    Agrochemicals and pesticides company whose Q1FY27 results drove a 10% intraday drop to a 52-week low.

  • PI Health Sciences Limited (PIHS)

    Pharma CDMO segment cited for a 25% YoY revenue contraction due to order book phasing and delivery schedules.

  • ICICI Securities

    Brokerage cited for attributing weakness to global demand softness and customer order timing.

Related articles

$PIHighAI 9/10

Impinj (PI) Q2 2026 Earnings Call Transcript

Impinj (PI) discussed progress in RFID reader and endpoint IC demand across supply chain and logistics, retail apparel, and food pilots using RAIN. In Q2 2026, revenue rose to $108.4M, up 46% sequentially and 11% YoY. Endpoint IC revenue was $96.4M. Gross margin hit 60.9%, and non-GAAP EPS was $0.86. Q3 revenue guidance was $105.5M to $108.5M.

$PIMed

5 Insightful Analyst Questions From Impinj’s Q2 Earnings Call

Impinj reported Q2 CY2026 revenue of $108.4 million versus $104.7 million expected, and adjusted EPS of $0.86 versus $0.80. Management cited strong endpoint IC bookings and demand across retail apparel, supply chain and logistics, and general merchandise, plus share gains. Q3 guidance calls for $107 million revenue and $0.61 adjusted EPS at the midpoint.

$PIMed

IMPINJ INC (PI): Results of Operations and Financial Condition

IMPINJ INC (PI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Impinj Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 29, 2026– Impinj, Inc. (Nasdaq: PI), a leading RAIN RFID provider and Internet of Things pioneer, today released its financial results for the second quarte

$APREMed

Aprea Therapeutics, Inc. (APRE): Results of Operations and Financial Condition

Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 apre-20260812xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ Aprea Therapeutics Announces Second Quarter 2026 Financial Results ​ Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea p